Global KSK7653 Market Strategic Research Report

Scope of the Report

The global KSK7653 market size is predicted to grow from US$ 27.88 million in 2025 to US$ 328 million in 2032; it is expected to grow at a CAGR of 25.6% from 2026 to 2032.

In 2025, global HSK7653 production reached approximately 180,000 units.HSK7653, with the generic name Cofogliptin, is a new type of dipeptidyl peptidase 4 (DPP-4) inhibitor antidiabetic drug independently developed by a domestic enterprise with independent intellectual property rights. By specifically inhibiting the activity of DPP-4 enzyme, this drug prolongs the action time of endogenous incretins in the body, thereby promoting insulin secretion, inhibiting glucagon release, achieving stable regulation of blood glucose, and is not prone to causing adverse reactions such as hypoglycemia. As an oral antidiabetic drug, HSK7653 features convenient administration and good tolerability. It is mainly used for the treatment of type 2 diabetes, which can effectively improve the blood glucose control level of patients, provide a safe and efficient treatment option for patients with type 2 diabetes, and at the same time promote the independent innovation and development of the domestic antidiabetic drug field.

HSK7653 (generic name: Cofogliptin), as the world's first ultra-long-acting dipeptidyl peptidase 4 (DPP-4) inhibitor, occupies a differentiated competitive position in the field of type 2 diabetes treatment by virtue of its unique advantage of biweekly oral administration, showing significant market development potential. As an innovative drug independently developed by a domestic enterprise, this drug has complete independent intellectual property rights, breaking the long-term monopoly of imported DPP-4 inhibitors in the market and conforming to the development trend of independent innovation in the domestic antidiabetic drug field. Its mechanism of action has the characteristics of glucose-dependent "intelligent hypoglycemia", with good safety and tolerability, no obvious risk of hypoglycemia and neutral impact on body weight. It is suitable for special patient groups such as the elderly and those with renal insufficiency, with a wide range of clinical application scenarios and continuously improving recognition. At present, the global DPP-4 inhibitor market is in a stage of steady development, with both competition between imported original drugs and domestic generic drugs, as well as differentiated breakthroughs of new ultra-long-acting preparations. Relying on its core advantage of ultra-long-acting administration, HSK7653 is different from traditional daily and weekly preparations, effectively improving patient medication adherence and forming unique market competitiveness. With the advancement of medical insurance access, further exploration of clinical indications and expansion of combination therapy regimens, the market penetration of this drug will continue to strengthen. At the same time, relying on the cost and channel advantages of domestic innovative drugs, it will gradually expand its market coverage, which is expected to seize more market share in the fierce market competition, help reshape the pattern of the domestic DPP-4 inhibitor market, provide a more convenient and safe treatment option for patients with type 2 diabetes, and promote the diversified development of the domestic antidiabetic drug market.

Key Questions Addressed in this Report

What is the 10-year outlook for the global KSK7653 market?

What factors are driving KSK7653 market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do KSK7653 market opportunities vary by end market size?

How does KSK7653 break out by Type, by Application?

This report presents a comprehensive overview of the global KSK7653 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 15 Mg / Tablet
• 30 Mg / Tablet

Segment by Combination Therapy

• HSK7653 + Metformin Combination
• HSK7653 + Sitagliptin Combination

Segment by Sales Channel

• Hospital
• Retail
• Online

Segment by Application

• Type 2 Diabetes Mellitus
• Insulin Resistance
• Metabolic Syndrome
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global KSK7653 market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Type 2 Diabetes Mellitus, Insulin Resistance, Metabolic Syndrome evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact